Genetically modified tumour vaccines--where we are today.
about
Differential baseline and response profile to IFN-gamma gene transduction of IL-6/IL-6 receptor-alpha secretion discriminate primary tumors versus bone marrow metastases of nasopharyngeal carcinomas in culture.Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.MUC1 immunotherapy against a metastatic mammary adenocarcinoma model: Importance of IFN-gamma.
P2860
Genetically modified tumour vaccines--where we are today.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Genetically modified tumour vaccines--where we are today.
@ast
Genetically modified tumour vaccines--where we are today.
@en
type
label
Genetically modified tumour vaccines--where we are today.
@ast
Genetically modified tumour vaccines--where we are today.
@en
prefLabel
Genetically modified tumour vaccines--where we are today.
@ast
Genetically modified tumour vaccines--where we are today.
@en
P356
P1476
Genetically modified tumour vaccines--where we are today
@en
P2093
Mackiewicz A
P356
10.1053/CTRV.1998.0104
P577
1999-02-01T00:00:00Z